Which company produces avatrombopag, and how does the brand background affect patient choice?

Avatrombopag/Suxin (Avatrombopag) was originally developed by the biopharmaceutical company Eisai (Eisai), and was later acquired by Novartis (Novartis). Part of its global rights. Currently, it has been approved by regulatory agencies for marketing in many countries and regions, including the United States, Europe, Japan and China, and has become one of the important targeted drugs for the treatment of chronic thrombocytopenia.

Eisai is a global pharmaceutical company headquartered in Tokyo, Japan. It specializes in research and development in the fields of neurology and oncology, especially focusing on the innovation of high value-added rare diseases and chronic disease drugs. The development of avatrombopag is based on Eisai's in-depth research on the hematopoietic regulatory mechanism. The drug was approved by the US FDA in 2018 and was initially used for patients with preoperative thrombocytopenia in chronic liver disease. It was later expanded to patients with chronic immune thrombocytopenia (ITP) and was included in the treatment plan recommended by the NCCN guidelines.

Su Kexin entered the Chinese market and was jointly introduced and promoted by Jiangsu Hengrui Pharmaceuticals and Eisai China. It was subsequently approved by the State Food and Drug Administration for the treatment of preoperative thrombocytopenia in chronic liver disease, and will be expanded for the treatment of chronic ITP in adults in 2021. It has also been included in the national medical insurance drug catalog, significantly reducing the financial burden on patients.

Brand background is not only related to drug research and development capabilities, but also directly affects drug quality control, drug accessibility, and patients' confidence in efficacy and safety. First-line pharmaceutical companies such as Eisai and Novartis have extensive experience in global clinical trials, drug regulatory communication, and real-world data construction, which can ensure continuous optimization and safety tracking of drugs after they are launched.

In addition, the brand difference between original drugs and generic drugs is also a concern for patients. Avatrombopag still exists as an original researcher, and there is no officially marketed generic version, which means that its efficacy and safety are more fully supported by clinical data. For patients with chronic ITP who need long-term management of platelet levels, choosing a brand with a strong R&D background and regulatory certification will be more conducive to stable disease control.

Reference materials:https://go.drugbank.com/drugs/DB11995